Alantra advised on the sale of Seabrook International to ARCH Global Precision
Boston–Alantra is pleased to announce that it advised Seabrook International in the sale of its business to ARCH Global Precision, a portfolio company of Strength Capital.The transaction was done for the benefit of Seabrook’s primary investors, whose investment is managed by Prudential Capital Group, and investment arm of PGIM, Inc. Alantra worked closely with the investor group on the transaction, which closed on January 9, 2017.
Founded in 1973, Seabrook International is a New Hampshire-based contract manufacturer of precision machined orthopaedic medical devices. The company supplies leading orthopaedic OEMs with surgical implants, devices and instruments for use during complex spine, knee and trauma related procedures. Products include high quality cutting guides, screw drivers and assemblies as well as custom, made-to-order instruments with turnaround times measured in days instead of weeks.
“Seabrook’s robust manufacturing capabilities and experienced management team will certainly be a strong addition to ARCH’s growing medical business,” said Chris Donegan, Managing Director at Alantra.According to the ARCH Global Precision website, Seabrook is the third medical acquisition completed by the company in the past 10 months. “The ARCH and Seabrook management teams recognized the strong strategic fit between the two companies upon first meeting so we are pleased to have assisted them in bringing the businesses together,” added Wade Aust, Managing Director and Partner at Alantra.
“This latest acquisition confirms our commitment to building a medical business with vast capabilities, a breadth of product offerings and a diverse customer base,” stated Eli Crotzer, ARCH Global Precision President and Chief Executive Officer, in a company statement. “Seabrook strengthens our existing capabilities in the manufacturing of complex single and multi-assembly instruments, in addition to adding a broader range of implants for various types of medical procedures we have not supported in the past. Seabrook has a highly skilled and experienced management team who we look forward to partnering with during the next stage of growth. Moreover, Seabrook’s current President and CEO, Paul Barck, is assuming the role of Divisional President of ARCH Medical Solutions.”
Dec 2021Growth investmentDec 2021SECTOR HealthcareService Strategic Advisory
Dec 2021Debt Capital MarketsValue €230 millionDec 2021SECTOR HealthcareService Debt AdvisoryValue €230 million
Nov 2021Private placement and Equity raisingNov 2021SECTOR HealthcareService Equity Capital Markets
Nov 2021Sell-side advisoryValue $47.4 millionNov 2021SECTOR HealthcareService M&AValue $47.4 million